Infographic: A History of Swedish Innovation in Protein Analysis

How the proteome behaves in healthy individuals

Clinical research, Multiomics
To achieve the goal of precision medicine, not only do different molecular profiles need to be understood in disease populations, but they must also be understood in the context of healthy populations.

Key proteomics publications from 2020

Proteomics
Welcome to the first post of the all-new weekly Olink to Science! Our customer survey revealed that you would like to know more about the many publications, research, and other science happening at Olink, therefore this blog aims to do just that: keep you informed on the exciting science taking place with our technology.

Protein biomarkers are crucial in early detection of cancer

Clinical research, Oncology, Protein biomarkers
A central premise of precision medicine is to identify biomarkers indicative of disease transitions early on. This is especially important in cancer where early treatment intervention could increase a patient’s chance of survival and reduce the probability of cancer recurrence.

Using PEA and RNA-Seq to study disease pathology

Clinical research, Proteomics
The following study illustrates how transcriptomics and proteomics complement one another to clarify the pathology of a complex, and little understood disease. Atopic dermatitis (AD) is the most common chronic skin condition affecting up to 20% of children and 7-10% of adults, depending on the population.

Olink protein biomarker panel indicates fermented foods fight inflammation

Inflammation, Proteomics
Could food be used to fight chronic disease?

Study identifies proteins involved in immunotherapy response

Oncology, Proteomics
'Ultimately, it is all about understanding and treating patients better in the future.'

Proteins diagnostic of lung cancer up to 5 years before disease onset

Oncology
An earlier Olink to Science blog post covered some amazing research that found that certain blood protein biomarkers have the potential to predict cancer up to 3 years before diagnosis. This may also be the case for lung cancer, as detailed in a recent study by Dagnino and her colleagues, where elevated levels of CDCP1 were detected in participants of a cohort who later developed the disease.

Utilizing proteogenomics technology for novel drug target discovery

Drug discovery & development
High-throughput multiplexed proteomic technology is leading the way to the latest developments in pre-clinical disease analysis in drug discovery. The pharmaceutical industry is now increasing its efforts in the discovery of novel drug targets by using protein quantitative trait loci (pQTLs), which allows for a more confident inference of disease causality and associated protein regulation.

Developing a high-performance biomarker panel for Alzheimer’s disease

Clinical research, Neurology, Protein biomarkers
A simple search of the term ‘scourge of Alzheimer’s Disease’ brings up over half a million website hits. A major disease, about 15% of us that reach the age of 67 to 74, and 44% of those 75 to 84 will develop AD.

How proteomics helped diabetic kidney disease research advance

Clinical research, Proteomics
Dr. Krolewski and his team at the Harvard Medical School found 56 proteins to be significant in diabetic kidney disease patients. Potentially, these could serve as prognostic biomarkers for disease progression and treatment response. This is how adding proteomics to the methodologies elevated their research.